Rockefeller University-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Rockefeller University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013583
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Rockefeller University (Rockefeller) is a biomedical research university that provides graduate and postdoctoral educational programs. The university offers various educational courses in the fields of biomedical sciences, chemistry, bioinformatics and physics. It conducts clinical studies in the areas of addictive diseases, auditory studies, blood disorders, cancer, immunology, neurologic and psychiatric disorders, and others. Rockefeller offers research services in chemical and structural biology, genetics and genomics, molecular and cell biology, neurosciences and behavior, immunology, virology and microbiology, medical sciences, systems physiology and human genetics, organismal biology, evolution, ethology and ecology, physical, mathematical and computational biology, stem cells, development, and regeneration and aging. The university provides professional and financial support services. Rockefeller is headquartered in New York, the US.

Rockefeller University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Rockefeller University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rockefeller University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Rockefeller University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rockefeller University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Rockefeller University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Rockefeller University, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
ContraFect Enters into Research Agreement with Rockefeller University 11
MabVax Therapeutics Enters into Research Agreement with Rockefeller University 12
QR Pharma Enters into Research Agreement with Rockefeller University 13
Licensing Agreements 14
Frontier Biotechnologies Enters into Licensing Agreement with Rockefeller University 14
Cerevance Enters into Licensing Agreement with Rockefeller University 15
ContraFect Enters into Licensing Agreement with Rockefeller University for lysine CF-301 16
ContraFect Enters Into Licensing Agreement With Rockefeller University 17
Lodo Therapeutics Enters into Licensing Agreement with Rockefeller University 18
Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 19
NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 21
Rockefeller University – Key Competitors 22
Rockefeller University – Key Employees 23
Rockefeller University – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Joint Venture 24
Recent Developments 25
Strategy And Business Planning 25
Oct 31, 2016: Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept 25
Government and Public Interest 27
Nov 02, 2017: Potential new treatment for Fragile X targets one gene to affect many 27
Jul 24, 2017: Researchers develop new method to generate human antibodies 28
Jun 09, 2017: NIH Funds NYC Center for AIDS Research 29
Mar 06, 2017: A new way to reset gene expression in cancer cells shows promise for leukemia treatment 30
Feb 24, 2017: New structural studies reveal workings of a molecular pump that ejects cancer drugs 32
Feb 03, 2017: Atomic-scale view of bacterial proteins offers path to new tuberculosis drugs 33
Dec 06, 2016: Researchers discover a new gatekeeper controlling T cell release into the bloodstream 34
Nov 23, 2016: Study shows low-dose chemotherapy regimens could prevent tumor recurrence in some cancers 35
Sep 29, 2016: Rockefeller University awarded $27 million NIH grant to fund clinical and translational science in Hospital 36
Sep 22, 2016: A compound that stops cells from making protein factories could lead to new antifungal drugs 37
Jul 13, 2016: The Wistar Institute and Partners Receive Nearly $23 Million from NIH to Advance HIV Cure Research 38
May 30, 2016: A combined approach to treating metastatic melanoma 39
Apr 25, 2016: Fisher Center Scientists Discover Pathway That may Lead to Alzheimer’s Disease 40
Mar 01, 2016: New research clarifies how stem cells get activated to produce new hair—and what happens when their regenerative powers wear out 41
Feb 03, 2016: Study reveals how herpes virus tricks the immune system 42
Jan 14, 2016: Signals that make early stem cells identified 43
Product News 45
05/05/2016: Broadly neutralizing antibodies improve immune response; clear HIV reservoirs 45
02/06/2017: Encouraging clinical results for an antibody drug to prevent or treat HIV 46
01/17/2017: Successful antibody trial in HIV-infected individuals 47
Clinical Trials 48
May 06, 2016: Antibody therapy opens door to potential new treatment for HIV 48
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Rockefeller University, Pharmaceuticals & Healthcare, Key Facts 2
Rockefeller University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rockefeller University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Rockefeller University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rockefeller University, Deals By Therapy Area, 2011 to YTD 2017 9
Rockefeller University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ContraFect Enters into Research Agreement with Rockefeller University 11
MabVax Therapeutics Enters into Research Agreement with Rockefeller University 12
QR Pharma Enters into Research Agreement with Rockefeller University 13
Frontier Biotechnologies Enters into Licensing Agreement with Rockefeller University 14
Cerevance Enters into Licensing Agreement with Rockefeller University 15
ContraFect Enters into Licensing Agreement with Rockefeller University for lysine CF-301 16
ContraFect Enters Into Licensing Agreement With Rockefeller University 17
Lodo Therapeutics Enters into Licensing Agreement with Rockefeller University 18
Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 19
NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 21
Rockefeller University, Key Competitors 22
Rockefeller University, Key Employees 23
Rockefeller University, Joint Venture 24

★海外企業調査レポート[Rockefeller University-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Varian Medical Systems, Inc.:企業のM&A・事業提携・投資動向
    Varian Medical Systems, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Varian Medical Systems, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Nuo Therapeutics Inc (AURX):製薬・医療:M&Aディール及び事業提携情報
    Summary Nuo Therapeutics Inc (Nuo Therapeutics), formerly Cytomedix, is a biomedical company that specializes in biodynamic therapies in the area of wound care. It focuses on commercializing cell-based technologies, which bind the regenerative capacity of the human body to trigger natural healing. T …
  • Diplomat Pharmacy Inc (DPLO):企業の財務・戦略的SWOT分析
    Diplomat Pharmacy Inc (DPLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • GSS Infotech Limited (GSS):企業の財務・戦略的SWOT分析
    GSS Infotech Limited (GSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Nissan Motor Co Ltd (7201):企業の財務・戦略的SWOT分析
    Nissan Motor Co Ltd (7201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Kiromic Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Kiromic Inc (Kiromic) is a biotechnology company focused on developing immuno-oncology therapies. Its pipeline products include BSK01, an injectable drug that harness dendritic cells for the treatment of solid and hematological malignancies; BSK02, a synthetic oral cancer immunotherapy compo …
  • Tulip Star Hotels Limited:企業の戦略・SWOT・財務分析
    Tulip Star Hotels Limited - Strategy, SWOT and Corporate Finance Report Summary Tulip Star Hotels Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Misonix Inc (MSON):企業の財務・戦略的SWOT分析
    Misonix Inc (MSON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Bose Corporation:企業の戦略・SWOT・財務情報
    Bose Corporation - Strategy, SWOT and Corporate Finance Report Summary Bose Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Nayara Energy Ltd.:企業の戦略・SWOT・財務分析
    Nayara Energy Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nayara Energy Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Hang Seng Bank Ltd:企業の戦略・SWOT・財務分析
    Hang Seng Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Hang Seng Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Dragon Oil Plc:企業の戦略的SWOT分析
    Dragon Oil Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Safe Orthopaedics SA (SAFOR):企業の製品パイプライン分析2018
    Summary Safe Orthopaedics SA (Safe Orthopaedics) is medical device company that manufactures and markets devices for spinal surgery. The company’s products comprise implants and surgical instruments. It offers modular cervical cages, percutaneous auto-correction screws, modular anchorage screws, per …
  • Absorption Systems LP-医療機器分野:企業M&A・提携分析
    Summary Absorption Systems LP (Absorption Systems) is a pre-clinical contract research organization that develops and implements research tools. The organization carries out preclinical testing of drugs, biologics, and medical devices. It develops and implements research tools to predict human outco …
  • Questerre Energy Corp (QEC):企業の財務・戦略的SWOT分析
    Summary Questerre Energy Corp (Questerre) is an independent oil and gas exploration and development company that acquires, explores, develops and produces unconventional oil and gas properties. The company’s unconventional properties include tight oil, shale oil and shale gas. It has base production …
  • Saras S.p.A. (SRS):電力:M&Aディール及び事業提携情報
    Summary Saras S.p.A. (Saras) is crude oil refiner and operates refining, marketing, power generation and wind power businesses. The company’s major refinery is Sarroch refinery, on the Southwestern coast of Sardinia. Saras is also active in the production and sale of electricity, and offers industri …
  • AU Optronics Corp.:企業の戦略・SWOT・財務分析
    AU Optronics Corp. - Strategy, SWOT and Corporate Finance Report Summary AU Optronics Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Smith Micro Software Inc (SMSI):企業の財務・戦略的SWOT分析
    Summary Smith Micro Software Inc (Smith Micro) is a software development company that develops productivity and graphic software products for professional artists and general consumers. The company offers products such as NetWise, QuickLink, consumer and CommSuite products. Its NetWise products comp …
  • MetaStat Inc (MTST)-製薬・医療分野:企業M&A・提携分析
    Summary MetaStat Inc (MetaStat) is a biotechnology company that discovers and develops personalized diagnostic and therapeutic treatment solutions for cancer patients. The company develops therapeutic product candidates based on novel approach that offers intracellular Mena protein isoforms drugable …
  • Gammon Construction Ltd:企業の戦略的SWOT分析
    Gammon Construction Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆